CGEN Stock — Price, Charts & Analysis

Compugen Ltd. (CGEN) has a trailing P/E of 7.01x and a forward P/E of -7.27x. This places CGEN in a lower earnings multiple territory based on the valuation data currently available on Worldtickers.

CGEN trades with 7.01x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether CGEN looks overvalued or undervalued.

CGEN's P/E of 7.01x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

CGEN's trailing EPS is $0.38 and forward EPS is -$0.37.

EPS, or earnings per share, shows how much profit Compugen Ltd. generated for each share. CGEN's trailing EPS is $0.38, and investors usually prefer EPS that is positive and growing over time.

Compugen Ltd. has a market cap of $252.44M, making CGEN a small-cap stock based on the current market value shown on Worldtickers.

CGEN's latest stock price on Worldtickers is $2.67. The latest move is $0.01 or 0.57%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

CGEN's quote includes a latest price of $2.67. The market open is $2.64. Previous close is $2.65. The intraday range is $2.63 to $2.77.

CGEN is up in the latest quote, with a move of $0.01 or 0.57%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

CGEN generated $74.00M in trailing revenue. Revenue growth is 107.00%, which helps show whether demand is expanding or slowing.

CGEN's revenue growth is 107.00%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, CGEN shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $35.19M.

Gross margin is 86.89%. Margins show how efficiently Compugen Ltd. turns revenue into profit.

Compugen Ltd. carries $3.02M and holds $125.30M in cash.

CGEN holds $125.30M on its balance sheet.

CGEN's book value per share is $0.94.

Institutions hold 15.20% of CGEN shares. Insiders hold 2.11% of shares. Ownership mix helps investors understand how much of Compugen Ltd. is held by professional investors and company insiders.

CGEN has 94.72M shares outstanding. Float shares are 92.67M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for CGEN, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for CGEN is -$0.37. Revenue growth is 107.00%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

CGEN's trailing EPS is $0.38. Forward EPS is -$0.37. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

CGEN is in the Healthcare sector. Its earnings multiple is 7.01x. Its latest displayed growth metric is 107.00%. Compare these figures with sector peers before deciding whether Compugen Ltd. is stronger or weaker than average.

CGEN trades at $2.67. The stock trades at 7.01x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Compugen Ltd.'s fundamentals.

CGEN risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 2.78, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

CGEN should be compared with companies in Biotechnology. Its earnings multiple is 7.01x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Compugen Ltd. (CGEN) operates in Healthcare, specifically Biotechnology. Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/

CGEN trades on NasdaqCM. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

CGEN stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Compugen Ltd.'s official website listed on Worldtickers is cgen.com/investors. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Compugen Ltd. employs about 75 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Compugen Ltd. is headquartered in Holon, Israel. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

CGEN is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

CGEN has traded between $1.30 and $3.24 over the past 52 weeks. At $2.67, it is 17.75% below the high and 105.00% above the low. The 52-week range helps gauge long-term price momentum.

CGEN is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is $2.29 and its 200-day moving average is $2.12.

CGEN's RSI is 63.76. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

CGEN's latest RSI reading is 63.76, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for CGEN is near $2.17. Key resistance is near $2.68. Breaks above resistance or below support can change the short-term technical setup.

CGEN's nearest reported support level is $2.17. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

CGEN's nearest reported resistance level is $2.68. A breakout above resistance can improve momentum, especially when volume confirms the move.

CGEN trades about 334.77K shares daily on average. The latest displayed volume is 299.92K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

CGEN's MACD is 0.02, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

CGEN is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 63.76 (neutral). MACD is bullish. Nearest support is around $2.17. Resistance is around $2.68. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $2.39 (10.17% from price). MA50 is $2.29 (15.13% from price). MA200 is $2.12 (24.16% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. CGEN's MA20 is $2.39. MA50 is $2.29. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

CGEN's pivot is near $2.60. Support is near $2.17. Resistance is near $2.68. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for CGEN is near $2.44. The next upper resistance zone is near $2.77. These levels help define risk and possible follow-through zones after a breakout or breakdown.

CGEN's Bollinger range is roughly $2.19 to $2.60. Band width is near 17.20%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

CGEN's ATR-based typical daily range is about 4.58%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 299.92K shares. Average volume is about 334.77K shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

CGEN's all-time high shown on Worldtickers is $19.90. Its all-time low is $0.34. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

CGEN has a beta of 2.78, meaning it has historically been more volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.